Nachrichten zur Flexion Therapeutics Aktie

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., April 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…

Flexion out-licenses Zilretta in China

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics Announces ZILRETTA® License Agreement and Provides Business Update Amid Coronavirus Pandemic

BURLINGTON, Mass., April 01, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it has entered…

Flexion Therapeutics: Reporting Record Revenue On A Record Day For The Market

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Upside For Flexion Therapeutics Depends On How Well It Can Commercialize ZILRETTA In 2020

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics Inc (FLXN) Q4 2019 Earnings Call Transcript

FLXN earnings call for the period ending December 31, 2019....…

Flexion Therapeutics, Inc. (FLXN) CEO Mike Clayman on Q4 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics (FLXN) Reports Q4 Loss, Tops Revenue Estimates

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 12.87% and 0.65%, respectively, for the quarter ended December 2019. Do…

Flexion Q4 Zilretta sales up 149%

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics Names Melissa Layman Chief Commercial Officer

BURLINGTON, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Melissa Layman has…

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., March 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…

Will Flexion Therapeutics (FLXN) Report Negative Earnings Next Week- What You Should Know

Flexion Therapeutics (FLXN) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2019 Financial Results on March 12, 2020

BURLINGTON, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report…

Flexion Therapeutics (FLXN) Presents At Raymond James Institutional Investors Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics to Present at the 41st Annual Raymond James Institutional Investors Conference

BURLINGTON, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will be…

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…

Flexion Therapeutics: A Good Foundation For Growth In 2020

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion sees Zilretta sales as high as $135M this year

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2019 Revenue and Initial Revenue Guidance for 2020

BURLINGTON, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited revenue…

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…

Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

In a final push before the closing of the year, the FDA deemed it fit to clear even long pending…

Is the Options Market Predicting a Spike in Flexion (FLXN) Stock-

Investors need to pay close attention to Flexion (FLXN) stock based on the movements in the options market lately....…

Flexions (FLXN) Stock Up on FDA Approval for Zilretta sNDA

Flexions (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval....…

Flexion Therapeutics Is Flexing Its Muscles

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion: Sweet Clarity

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Flexion Therapeutics Stock Is Flying Higher Today

A key FDA decision could pave the way for higher sales of the companys flagship drug....…

Flexion Therapeutics shares soar after FDA approves change to label on knee pain treatment

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Analysts Say Long-Delayed Zilretta Label Expansion A Relief For Investors

Flexion Therapeutics Inc (NASDAQ: FLXN) shares are on a tear after the FDA approved an update this week of the…

Flexion Surges on FDA Label-Update Approval, Analyst Price-Target Lift

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mid-Morning Market Update: Markets Mostly Higher; Flexion Receives FDA Nod For Zilretta Label Expansion

Following the market opening Friday, the Dow traded up 0.15% to 28,664.55 while the NASDAQ fell 0.05% to 9,018.25. The…

Flexion Therapeutics stock soars 24% premarket as FDA approves label change for OA keen pain therapy

Shares of Flexion Therapeutics Inc. soared more than 24% in premarket trade Friday, after the company said the U.S.…

The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks…

Flexion +13% premarket as analysts weigh in on Zilretta label update

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics reiterated as buy at Benchmark

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA approves Flexions Zilretta product label update

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics Announces FDA Approval of sNDA to Revise ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Product Label

BURLINGTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the U.S. Food…

Flexion Awaits FDA Word On Revised Zilretta Label

Shares of Flexion Therapeutics Inc. (FLXN) are down nearly 14 percent from their 52-week high of $21.39, recorded as recently…

Flexion begins patient enrollment in mid-stage Zilretta trial

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Flexion Therapeutics Enrolls First Patients in Phase 2 Trial of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) in OA of the Shoulder and Adhesive Capsulitis

BURLINGTON, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that the first three…

Flexion Therapeutics to Host Physician Event at Orthopaedic Summit 2019 Featuring Panel of Former Professional Athletes Treated With ZILRETTA® for Osteoarthritis Knee Pain

BURLINGTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the speaker lineup for…

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to…

Flexion Therapeutics Presents ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Efficacy Data at the AAHKS and ACR Annual Meetings

BURLINGTON, Mass., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced results from a sensitivity…